Clinical Trials Browser

Phase 1/2 × Hematologic Neoplasms × Dexamethasone × Clear all

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT04752163 2025-05-23

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01084252 2024-11-01

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Phase 1/2 Completed

351 enrolled 56 charts

Other hematologic neoplasm

Hematologic Neoplasms

NCT05205252 2023-08-15

ARIA

Phase 1/2 Withdrawn

Other hematologic neoplasm

Hematologic Neoplasms

NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

Phase 1/2 Completed

58 enrolled 11 charts

Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Clinical Trials

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

ARIA

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)